Relation between cellular doxorubicin binding ability to nuclear DNA and histologic response to preoperative chemotherapy in patients with osteosarcoma

Cancer

Volumn 82, Issue 12, 1998, Pages 2343-2349

  Kusuzaki, Katsuyuki ^a   Takeshita, Hideyuki ^a   Murata, Hiroaki ^a   Hirata, Masazumi ^a   Hashiguchi, Shin ^a   Ashihara, Tsukasa ^a   Hirasawa, Yasusuke ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Adriamycin; Bone tumor; Chemosensitivity; Chemotherapy; Multidrug resistance; Osteosarcoma

Indexed keywords

CARBOPLATIN; CISPLATIN; DACTINOMYCIN; DOXORUBICIN; METHOTREXATE; PIRARUBICIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CHEMOSENSITIVITY; CHILD; CLINICAL ARTICLE; DNA DRUG COMPLEX; DRUG DETERMINATION; DRUG DNA BINDING; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; MALE; MULTIDRUG RESISTANCE; OSTEOSARCOMA; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; TUMOR NECROSIS;

EID: 0032525838     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980615)82:12<2343::AID-CNCR7>3.0.CO;2-T     Document Type: Article

References (29)

1. Bacci G, Picci P, Ruggieri P, Mercuri M, Avella M, Capanna R, et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of extremities. the Istituto Rizzoli experience in 127 patients treated pre-operatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer 1990;65: 2539-53.
2. Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992; 10:5-15.
3. Bacci G, Picci P, Ferrari S, Orlandi M, Ruggieri P, Casadei R, et al. Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy. Cancer 1993;71: 1224-30.
4. Saeter G, Hoie J, Stenwig AE, Johansson AK, Hannisdal E, Solheim O. Systemic relapse of patients with osteogenic sarcoma, prognostic factors for long term survival. Cancer 1995;75:1084-93.
5. Von Hoff DD, Casper J, Bradley E, Sandbach J, Jones D, Makuch R. Association between human tumor colony-forming assay results and response of an individual patient's tumor to chemotherapy. Am J Med 1981;70:1027-32.
6. Brown E, Markman M. Tumor chemosensitivity and chemoresistance assays. Cancer 1996;77:1020-5.
7. Blaney SM, Smith MA, Grem JL. Doxorubicin: role in the treatment of osteosarcoma. Osteosarcoma in adolescents and young adults. Boston: Kluwer Academic Publishers, 1993:55-73.
8. Egorin MJ, Hildebrand RC, Cimino EF, Bachur NR. Cytofluorescence localization of adriamycin and dounorubicin. Cancer Res 1974;34:2243-5.
9. Kusuzaki K, Litwak GI, Gebhardt MC, Springfield DS, Mankin HJ. Assessment of intracellular adriamycin(Adr) binding in bone and soft-tissue tumor cells by fluorescence microscopy. Trans Orthop Res Soc 1989;14:549.
10. Weinstein MJ, Berg J, Kusuzaki K, Springfield DS, Gebhardt MC, Mankin HJ. In vitro assay of nuclear uptake of doxorubicin hydrochloride in osteosarcoma cells of dogs. Am J Vet Res 1991;52:1951-5
11. Baldini N, Scotlandi K, Serra M, Kusuzaki K, Shikita T, Manara MC, et al. Adriamycin binding assay: a valuable chemosensitivity test in human osteosarcoma. J Cancer Res Clin Oncol 1992;119:121-6.
12. Gebhardt MC, Kusuzaki K, Mankin HJ, Springfield DS. An assay to measure adriamycin binding in osteosarcoma cells. J Orthop Res 1994;12:621-7.
13. Takeshita H, Gebhardt MC, Springfield DS, Kusuzaki K, Mankin HJ. Experimental models for study of drug resistance in osteosarcoma: P-glycoprotein-positive, murine osteosarcoma cell lines. J Bone Joint Surg 1996;78A:366-75.
14. Jones KH, Senft JA. An improved method to determine cell viability by simultaneous staining with fluorescein diacetate-propidium iodide. J Histochem Cytochem 1985;33: 77-9.
15. Delling G, Krumme H, Salzer-Kuntschik M. Morphological changes in osteosarcoma after chemotherapy-COSS 80. J Cancer Res Clin Oncol 1983;106(Suppl):32-7.
16. Picci P, Sangiorgi L, Rougraff BT, Neff JR, Casadei R, Campanacci M. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol 1994;12:2699-705.
17. Taetle R, Honeysett JM, Rosen F, Shoemaker R. Use of nude mouse xenografts as preclinical drug screens. Further studies on in vitro growth of xenograft tumor colony-forming cells. Cancer 1986;58:1969-78.
18. Salmon SE, Hamburger AW, Soehnlen B, Durie BG, Alberts DS, Moon TE. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med 1978;298:1321-7.
19. Bech-Hansen NT, Saragi F, Sutherland DJA, Ling V. Rapid assay for evaluating the drug sensitivity of tumor cells. J Natl Cancer Inst 1977;59:21-7.
20. Bogden AE, Cobb WR, Lepage DJ, Haskell PM, Gulkin TA, Ward A, et al. Chemotherapy responsiveness of human tumors as first transplant generation xenografts in the normal mouse: six-day subrenal capsule assay. Cancer 1981;48:10-20.
21. Biedler JL. Genetic aspects of multidrug resistance. Cancer 1992;70:1799-809.
22. Goldstein LJ. Clinical reversal of resistance. Curr Prob Cancer 1995;19:67-123.
23. Chan HSL, DeBoer G, Haddad G, Gallie B, Ling V. Multidrug resistance in pediatric malignancies. Hematol Oncol Clin N Am 1995:9;275-317.
24. Shustik C, Dalton W, Gros P. P-glycoprotein-mediated multidrug resistance in tumor cells: Biochemistry, clinical relevance and modulation. Mol Aspects Med 1995;16:1-78.
25. Skinner KA, Eliber FR, Holmes EC, Eckardt J, Rosen G. Surgical treatment and chemotherapy for pulmonary metastases from osteosarcoma. Arch Surg 1992;127:1065-71.
26. Stein U, Wunderlich V, Haensch W, Schmidt-Peter P. Expression of the mdr 1 gene in bone and soft tissue sarcomas of adult patients. Eur J Cancer 1993;29A:1979-81.
27. Wunder JS, Bell RS, Wold L, Andrulis IL. Expression of the multidrug resistance gene in osteosarcoma: a pilot study. J Orthop Res 1993;11:396-403.
28. Baldini N, Scotlandi K, Barbanti-Brodano G, Manara MC, Maurici D, Bacci G, et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl Med 1995;333:1380-5.
29. Taguchi Y, Yoshida A, Takada Y, Komano T, Ueda K. Anticancer drugs and glutathione stimulate vanadate-induced trapping of nucleotide in multidrug resistance-associated protein (MRP). FEBS Lett 1997;401:11-4.